YONKERS, N.Y., Oct. 13, 2009 (GLOBE NEWSWIRE) -- Aureon Laboratories, Inc. today announced the hiring of David Brown as Vice President of Sales. Mr. Brown will provide leadership to the sales team and help oversee the company's planned expansion into new markets.
Prior to joining Aureon Mr. Brown held senior sales and marketing leadership positions with Covidien as Vice President of Sales and Marketing and VP of Global Market Development, with Smith and Nephew as VP of Strategic Sales, and most recently with Salient Surgical Technologies as the VP of Sales and Marketing. During his 20 years in the medical device industry he has gained significant experience in building and leading best in class sales teams, developing and implementing go to market strategies and working with leading surgeons and institutions to implement technologies that have significantly improved patient care.
"I am very pleased to join the strong management team at Aureon, and help them usher in a new era of medicine where surgeons and patients are able to utilize enhanced patient specific data to make more informed treatment decisions," said David Brown. "I'm excited to help the company leverage its products, most notably Prostate Px+, in this rapidly growing marketplace."
Prostate Px+ helps newly diagnosed patients make more informed treatment decisions by providing an objective and personalized analysis of the patient's cancer at the molecular level. Prostate Px+ successfully identifies patients with aggressive, life-threatening prostate cancer with greater accuracy than any other method currently available.
"David's extensive track record of leadership and success will make him an immediate asset to our organization," said Robert Shovlin, President and CEO of Aureon Laboratories. "We are very excited to add David to our growing team as we prepare for our next phase of growth and expansion."
Mr. Brown received his undergraduate degree in Business Administration from Penn State University.
About Aureon Laboratories
Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit www.aureon.com or call 1-888-SYS-PATH.
The Aureon Laboratories logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6360